Published in Sci Signal on September 11, 2012
Exosome secretion is enhanced by invadopodia and drives invasive behavior. Cell Rep (2013) 1.26
Signaling inputs to invadopodia and podosomes. J Cell Sci (2013) 1.18
Tks5 and SHIP2 regulate invadopodium maturation, but not initiation, in breast carcinoma cells. Curr Biol (2013) 1.11
The netrin receptor DCC focuses invadopodia-driven basement membrane transmigration in vivo. J Cell Biol (2013) 1.11
Integrin-matrix clusters form podosome-like adhesions in the absence of traction forces. Cell Rep (2013) 0.98
Cdc42 and Tks5: a minimal and universal molecular signature for functional invadosomes. Cell Adh Migr (2014) 0.95
FAK competes for Src to promote migration against invasion in melanoma cells. Cell Death Dis (2014) 0.87
Invadopodia in context. Cell Adh Migr (2014) 0.84
Quantitative proteomic analysis reveals effects of epidermal growth factor receptor (EGFR) on invasion-promoting proteins secreted by glioblastoma cells. Mol Cell Proteomics (2014) 0.84
Invadopodia and basement membrane invasion in vivo. Cell Adh Migr (2014) 0.83
Regulation of ECM degradation and axon guidance by growth cone invadosomes. Development (2015) 0.83
Phosphoinositide 3-kinase p85beta regulates invadopodium formation. Biol Open (2014) 0.82
ABL tyrosine kinase inhibition variable effects on the invasive properties of different triple negative breast cancer cell lines. PLoS One (2015) 0.82
Cell invasion through basement membrane: The netrin receptor DCC guides the way. Worm (2013) 0.80
Linking patient outcome to high throughput protein expression data identifies novel regulators of colorectal adenocarcinoma aggressiveness. F1000Res (2015) 0.80
Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies. JAMA Otolaryngol Head Neck Surg (2015) 0.79
MicroRNA-375 Suppresses Extracellular Matrix Degradation and Invadopodial Activity in Head and Neck Squamous Cell Carcinoma. Arch Pathol Lab Med (2015) 0.79
Regulation of invadopodia by the tumor microenvironment. Cell Adh Migr (2014) 0.78
5'-Inositol phosphatase SHIP2 recruits Mena to stabilize invadopodia for cancer cell invasion. J Cell Biol (2016) 0.78
Force-dependent breaching of the basement membrane. Matrix Biol (2016) 0.78
Automated analysis of invadopodia dynamics in live cells. PeerJ (2014) 0.77
The phosphoinositide-binding protein ZF21 regulates ECM degradation by invadopodia. PLoS One (2013) 0.77
Protein tyrosine phosphatase SHP2 promotes invadopodia formation through suppression of Rho signaling. Oncotarget (2015) 0.77
Mechanotransduction at focal adhesions: from physiology to cancer development. J Cell Mol Med (2013) 0.77
Phosphatidylinositolphosphate phosphatase activities and cancer. J Lipid Res (2015) 0.76
Dual inhibition of Type I and Type III PI3 kinases increases tumor cell apoptosis in HER2+ breast cancers. Breast Cancer Res (2015) 0.75
Cell adhesion and invasion mechanisms that guide developing axons. Curr Opin Neurobiol (2016) 0.75
A RhoG-mediated signaling pathway that modulates invadopodia dynamics in breast cancer cells. J Cell Sci (2017) 0.75
LPP is a Src substrate required for invadopodia formation and efficient breast cancer lung metastasis. Nat Commun (2017) 0.75
PKCα promotes the mesenchymal to amoeboid transition and increases cancer cell invasiveness. BMC Cancer (2015) 0.75
Matrix rigidity differentially regulates invadopodia activity through ROCK1 and ROCK2. Biomaterials (2016) 0.75
5-Azacytidine promotes invadopodia formation and tumor metastasis through the upregulation of PI3K in ovarian cancer cells. Oncotarget (2017) 0.75
The hallmarks of cancer. Cell (2000) 113.05
Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res (2003) 103.76
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (1997) 29.34
Human Protein Reference Database--2009 update. Nucleic Acids Res (2008) 21.25
Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature (2012) 15.91
Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov (2009) 10.59
Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther (2006) 7.73
Walking the interactome for prioritization of candidate disease genes. Am J Hum Genet (2008) 7.03
Functional atlas of the integrin adhesome. Nat Cell Biol (2007) 6.89
Dynamic modularity in protein interaction networks predicts breast cancer outcome. Nat Biotechnol (2009) 5.41
Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res (2005) 5.07
Foot and mouth: podosomes, invadopodia and circular dorsal ruffles. Nat Rev Mol Cell Biol (2004) 4.35
The 'ins' and 'outs' of podosomes and invadopodia: characteristics, formation and function. Nat Rev Mol Cell Biol (2011) 4.24
Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol (2009) 4.07
Integrins in mechanotransduction. J Biol Chem (2004) 3.57
Formation of regulatory patterns during signal propagation in a Mammalian cellular network. Science (2005) 3.48
Rous sarcoma virus-transformed fibroblasts adhere primarily at discrete protrusions of the ventral membrane called podosomes. Exp Cell Res (1985) 3.41
A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. Clin Proteomics (2010) 3.25
Invadopodia: specialized cell structures for cancer invasion. Clin Exp Metastasis (2006) 3.05
Matrix invasion by tumour cells: a focus on MT1-MMP trafficking to invadopodia. J Cell Sci (2009) 2.94
The adaptor protein Tks5/Fish is required for podosome formation and function, and for the protease-driven invasion of cancer cells. Cancer Cell (2005) 2.91
Supervised clustering of genes. Genome Biol (2002) 2.86
c-Src enhances the spreading of src-/- fibroblasts on fibronectin by a kinase-independent mechanism. Genes Dev (1995) 2.72
The PTEN/MMAC1 tumor suppressor induces cell death that is rescued by the AKT/protein kinase B oncogene. Cancer Res (1998) 2.32
Targeting the protein kinase C family: are we there yet? Nat Rev Cancer (2007) 2.29
Zyxin: zinc fingers at sites of cell adhesion. Bioessays (1997) 2.21
Sequential signals toward podosome formation in NIH-src cells. J Cell Biol (2008) 2.18
Unveiling the role of network and systems biology in drug discovery. Trends Pharmacol Sci (2010) 2.06
The role of the inositol polyphosphate 5-phosphatases in cellular function and human disease. Biochem J (2009) 1.97
FAK alters invadopodia and focal adhesion composition and dynamics to regulate breast cancer invasion. J Cell Biol (2009) 1.97
Cytoskeletal regulation: rich in lipids. Nat Rev Mol Cell Biol (2004) 1.94
Predictors of recurrence in thymic tumors: importance of invasion, World Health Organization histology, and size. J Thorac Cardiovasc Surg (2005) 1.73
Proteins, drug targets and the mechanisms they control: the simple truth about complex networks. Nat Rev Drug Discov (2007) 1.73
Invadosomes at a glance. J Cell Sci (2009) 1.70
Role of synaptojanin 2 in glioma cell migration and invasion. Cancer Res (2004) 1.64
A potential marker protease of invasiveness, seprase, is localized on invadopodia of human malignant melanoma cells. Cancer Res (1994) 1.63
Invasive matrix degradation at focal adhesions occurs via protease recruitment by a FAK-p130Cas complex. J Cell Biol (2012) 1.59
Phosphoinositide 3-kinase signaling pathway mediated by p110α regulates invadopodia formation. J Cell Biol (2011) 1.56
MT1-MMP-dependent invasion is regulated by TI-VAMP/VAMP7. Curr Biol (2008) 1.55
Local degradation of fibronectin at sites of expression of the transforming gene product pp60src. Nature (1985) 1.55
Neuronal IP3 3-kinase is an F-actin-bundling protein: role in dendritic targeting and regulation of spine morphology. Mol Biol Cell (2009) 1.48
A signalling cascade involving PKC, Src and Cdc42 regulates podosome assembly in cultured endothelial cells in response to phorbol ester. J Cell Sci (2006) 1.44
A feed-forward loop involving protein kinase Calpha and microRNAs regulates tumor cell cycle. Cancer Res (2009) 1.43
Altered organization of cell-substrate contacts and membrane-associated cytoskeleton in tumor cell variants exhibiting different metastatic capabilities. Cancer Res (1982) 1.41
Podosome formation in cultured A7r5 vascular smooth muscle cells requires Arp2/3-dependent de-novo actin polymerization at discrete microdomains. J Cell Sci (2003) 1.38
Genetic and epigenetic heterogeneity in cancer: a genome-centric perspective. J Cell Physiol (2009) 1.37
PKCalpha expression is a marker for breast cancer aggressiveness. Mol Cancer (2010) 1.34
Establishment and validation of computational model for MT1-MMP dependent ECM degradation and intervention strategies. PLoS Comput Biol (2012) 1.33
Protein kinase Calpha activates c-Src and induces podosome formation via AFAP-110. Mol Cell Biol (2004) 1.33
Classical PKC isoforms in cancer. Pharmacol Res (2007) 1.29
Regulation of protein kinase C and role in cancer biology. Cancer Metastasis Rev (1994) 1.25
Insights into the organization of biochemical regulatory networks using graph theory analyses. J Biol Chem (2008) 1.22
Immunohistochemical analysis of advanced human breast carcinomas reveals downregulation of protein kinase C alpha. J Histochem Cytochem (2004) 1.18
SH2-containing inositol 5'-phosphatase SHIP2 associates with the p130(Cas) adapter protein and regulates cellular adhesion and spreading. Mol Cell Biol (2001) 1.17
SnapShot: Protein-protein interaction networks. Cell (2011) 1.12
Inhibition of PI3K binding to activators by serine phosphorylation of PI3K regulatory subunit p85alpha Src homology-2 domains. Proc Natl Acad Sci U S A (2011) 1.06
hTERT phosphorylation by PKC is essential for telomerase holoprotein integrity and enzyme activity in head neck cancer cells. Br J Cancer (2006) 1.03
The protein kinase C cascade regulates recruitment of matrix metalloprotease 9 to podosomes and its release and activation. Mol Cell Biol (2010) 1.03
High expression of obesity-linked phosphatase SHIP2 in invasive breast cancer correlates with reduced disease-free survival. Tumour Biol (2008) 1.00
Membrane lipids in invadopodia and podosomes: key structures for cancer invasion and metastasis. Oncotarget (2010) 1.00
Relating protein adduction to gene expression changes: a systems approach. Mol Biosyst (2011) 0.99
Lymphovascular invasion is a significant predictor for distant recurrence in patients with early-stage endometrial endometrioid adenocarcinoma. Am J Clin Pathol (2008) 0.88
ZF21 protein regulates cell adhesion and motility. J Biol Chem (2010) 0.86
Phosphoinositide kinase-3 status associated with presence or absence of human papillomavirus in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys (2007) 0.86
Protein kinase C alpha expression in normal breast, ductal carcinoma in situ and invasive ductal carcinoma. Eur J Cancer (2004) 0.84
Quantification and visualization of phosphoinositides by quantum dot-labeled specific binding-domain probes. J Lipid Res (2012) 0.79
PKCalpha reduces the lipid kinase activity of the p110alpha/p85alpha PI3K through the phosphorylation of the catalytic subunit. Biochem Biophys Res Commun (2005) 0.77
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res (2006) 18.44
Use of proteomic patterns in serum to identify ovarian cancer. Lancet (2002) 16.38
Integrated genomic characterization of endometrial carcinoma. Nature (2013) 14.29
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov (2005) 11.46
The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet (2013) 11.29
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell (2007) 11.21
The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer (2009) 9.01
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res (2008) 8.12
Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther (2006) 7.73
The Genomes of Oryza sativa: a history of duplications. PLoS Biol (2005) 7.67
Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell (2012) 6.80
The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol (2007) 6.22
WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013. Nucleic Acids Res (2013) 6.17
Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med (2011) 6.15
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res (2009) 5.68
Characterization of the human heart mitochondrial proteome. Nat Biotechnol (2003) 5.66
Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol (2002) 5.52
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol (2008) 5.19
High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov (2011) 4.78
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell (2009) 4.71
The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med (2004) 4.69
Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J Biol Chem (2007) 4.60
Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci U S A (2011) 4.55
A module of negative feedback regulators defines growth factor signaling. Nat Genet (2007) 4.35
Derailed endocytosis: an emerging feature of cancer. Nat Rev Cancer (2008) 4.25
Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics (2005) 4.18
Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell (2006) 4.13
Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology (2009) 4.08
Cohort Profile: The China Health and Nutrition Survey--monitoring and understanding socio-economic and health change in China, 1989-2011. Int J Epidemiol (2009) 4.08
Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell (2006) 4.07
Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell (2004) 3.91
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep (2013) 3.85
Rab25 associates with alpha5beta1 integrin to promote invasive migration in 3D microenvironments. Dev Cell (2007) 3.84
A simplified laminin nomenclature. Matrix Biol (2005) 3.81
Rapid growth of a hepatocellular carcinoma and the driving mutations revealed by cell-population genetic analysis of whole-genome data. Proc Natl Acad Sci U S A (2011) 3.80
Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res (2005) 3.80
Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res (2005) 3.78
Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res (2009) 3.59
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res (2010) 3.53
Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest (2010) 3.53
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res (2012) 3.48
MT1-MMP: a potent modifier of pericellular microenvironment. J Cell Physiol (2006) 3.37
Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell (2009) 3.36
Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol (2006) 3.35
Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene (2003) 3.32
Cortactin is an essential regulator of matrix metalloproteinase secretion and extracellular matrix degradation in invadopodia. Cancer Res (2007) 3.30
A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. Clin Proteomics (2010) 3.25
Non-parametric quantification of protein lysate arrays. Bioinformatics (2007) 3.18
Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res (2009) 3.14
ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS. Proc Natl Acad Sci U S A (2010) 3.03
A genetically defined model for human ovarian cancer. Cancer Res (2004) 3.02
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Adult mouse epicardium modulates myocardial injury by secreting paracrine factors. J Clin Invest (2011) 2.99
Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res (2005) 2.98
Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci U S A (2005) 2.96
Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res (2004) 2.96
Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun (2013) 2.94
Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. Clin Cancer Res (2007) 2.94
Functional proteomic profiling of AML predicts response and survival. Blood (2008) 2.90
Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res (2007) 2.89
HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene (2003) 2.84
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A (2010) 2.79
The Drosophila BMP type II receptor Wishful Thinking regulates neuromuscular synapse morphology and function. Neuron (2002) 2.79
Cortactin promotes cell motility by enhancing lamellipodial persistence. Curr Biol (2005) 2.78
Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet (2009) 2.76
Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell (2012) 2.71
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov (2012) 2.68
The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci U S A (2006) 2.64
Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res (2011) 2.64
The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J Clin Invest (2008) 2.63
A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res (2013) 2.63
A new mutational AKTivation in the PI3K pathway. Cancer Cell (2007) 2.62
BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. Cancer Cell (2006) 2.61
Periprostatic adipose tissue as a modulator of prostate cancer aggressiveness. J Urol (2009) 2.54
Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res (2004) 2.50
PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther (2011) 2.50
Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst (2002) 2.45
Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res (2004) 2.44
Modeling precision treatment of breast cancer. Genome Biol (2013) 2.42
PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell (2013) 2.38
Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res (2002) 2.37
Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nat Med (2011) 2.34